PBH furnishes earnings release and investor slides on Nov 6, 2025

Rhea-AI Filing Summary

Prestige Consumer Healthcare (PBH) announced financial results for the fiscal quarter and six months ended September 30, 2025. The company furnished a press release detailing the results as Exhibit 99.1 and an investor presentation as Exhibit 99.2.

Management began using the investor presentation on November 6, 2025 and may use it during the fiscal year ending March 31, 2026. The materials in Items 2.02 and 7.01 and Exhibits 99.1 and 99.2 are furnished, not filed, and are not subject to Section 18 liabilities unless specifically stated otherwise.

8-K Event Classification

3 items: 2.02, 7.01, 9.01

3 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001295947false00012959472025-11-062025-11-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_______________________

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 6, 2025

PRESTIGE CONSUMER HEALTHCARE INC.

(Exact Name of Registrant as Specified in Charter)

 

Delaware

001-32433

20-1297589

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

660 White Plains Road, Tarrytown, New York 10591

(Address of Principal Executive Offices) (Zip Code)

(914) 524-6800

(Registrant's telephone number, including area code)

(Former Name or Former Address, if Changed Since Last Report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common stock, par value $0.01 per share			PBH			New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

☐

Item 2.02 Results of Operations and Financial Condition.

On November 6, 2025, Prestige Consumer Healthcare Inc. (the “Company”) announced financial results for the fiscal quarter and six months ended September 30, 2025. A copy of the press release announcing the Company's earnings results for the fiscal quarter and six months ended September 30, 2025 is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 7.01 Regulation FD Disclosure.

On November 6, 2025, representatives of the Company began making presentations to investors regarding the Company's financial results for the quarter and six months ended September 30, 2025 using slides attached to this Current Report on Form 8-K as Exhibit 99.2 (the “Investor Presentation”) and incorporated herein by reference.  The Company expects to use the Investor Presentation, in whole or in part, and possibly with modifications, in connection with presentations to investors, analysts and others during the fiscal year ended March 31, 2026.

By furnishing the information contained in this Item 7.01, the Company makes no admission as to the materiality of any information that is required to be disclosed solely by reason of Regulation FD.

The information contained in the Investor Presentation is summary information that is intended to be considered in the context of the Company's Securities and Exchange Commission (“SEC”) filings and other public announcements that the Company may make, by press release or otherwise, from time to time.  The Company undertakes no duty or obligation to publicly update or revise the information contained in this report, although it may do so from time to time as its management believes is warranted.  Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure.

The information presented in Items 2.02 and 7.01 of this Current Report on Form 8-K and Exhibits 99.1 and 99.2 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, unless the Company specifically states that the information is to be considered “filed” under the Exchange Act or specifically incorporates it by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act.

Item 9.01 Financial Statements and Exhibits.

(d)    Exhibits.

See Exhibit Index immediately following the signature page.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: November 6, 2025			PRESTIGE CONSUMER HEALTHCARE INC.
			By:			/s/ Christine Sacco
						Christine Sacco
						Chief Financial Officer & Chief Operating Officer

EXHIBIT INDEX

 

Exhibit						Description
99.1						Press Release dated November 6, 2025, announcing the Company's financial results for the fiscal quarter and six months ended September 30, 2025 (furnished only).
99.2						Investor Presentation in use beginning November 6, 2025 (furnished only).
104						Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document).

FAQ

What did PBH announce in this 8-K?

The company announced financial results for the fiscal quarter and six months ended September 30, 2025.

Which exhibits did PBH furnish with the 8-K?

PBH furnished Exhibit 99.1 (press release with results), Exhibit 99.2 (investor presentation), and Exhibit 104 (cover page Inline XBRL).

Are the earnings materials considered filed with the SEC?

No. The information in Items 2.02 and 7.01 and Exhibits 99.1 and 99.2 is furnished, not filed, unless specifically stated otherwise.

When did PBH begin using the investor presentation?

PBH began using the investor presentation on November 6, 2025 and may use it during the fiscal year ending March 31, 2026.

Which 8-K items are included?

The filing includes Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure).

Who signed the report for PBH?

It was signed by Christine Sacco, Chief Financial Officer & Chief Operating Officer, on November 6, 2025.